Anticancer activities of (−)-epigallocatechin-3-gallate encapsulated nanoliposomes in MCF7 breast cancer cells

References

• American Cancer Society. (2011). Breast Cancer Facts and Figures 2011--2012. Atlanta (GA): American Cancer Society, 1--27
   Google Scholar
• Barras A, Mezzetti A, Richard A, et al. (2009). Formulation and characterization of polyphenol-loaded lipid nanocapsules. Int J Pharm 379:270–7
   PubMed Web of Science ®Google Scholar
• Basu A, Lucas EA. (2007). Mechanisms and effects of green tea on cardiovascular health. Nutr Rev 65:361–75
   PubMed Web of Science ®Google Scholar
• Bigelow RL, Cardelli JA. (2006). The green tea catechins, (−)-Epigallocatechin-3-gallate (EGCG) and (−)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells. Oncogene 25:1922–30
   PubMed Web of Science ®Google Scholar
• Chen MC, Wong HS, Lin KJ, et al. (2009). The characteristics, biodistribution and bioavailability of a chitosan-based nanoparticulate system for the oral delivery of heparin. Biomaterials 30:6629–37
   PubMed Web of Science ®Google Scholar
• Chen Z, Wang S, Lee K, et al. (2001). Preparation of flavanol-rich green tea extract by precipitation with AlCl3. J Sci Food Agric 81:1034–8
   Google Scholar
• Chen ZP, Schell JB, Ho CT, Chen KY. (1998). Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts. Cancer Lett 129:173–9
   PubMed Web of Science ®Google Scholar
• Choi CH, Zuckerman JE, Webster P, Davis ME. (2011). Targeting kidney mesangium by nanoparticles of defined size. Proc Natl Acad Sci USA 108:6656–61
   PubMed Web of Science ®Google Scholar
• Chyu KY, Babbidge SM, Zhao X, et al. (2004). Differential effects of green tea-derived catechin on developing versus established atherosclerosis in apolipoprotein E-null mice. Circulation 109:2448–53
   PubMed Web of Science ®Google Scholar
• Dou QP. (2009). Molecular mechanisms of green tea polyphenols. Nutr Cancer 61:827–35
   PubMed Web of Science ®Google Scholar
• Dube A, Nicolazzo JA, Larson I. (2010). Chitosan nanoparticles enhance the intestinal absorption of the green tea catechins (+)-catechin and (−)-epigallocatechin gallate. Eur J Pharm Sci 41:219–25
   PubMed Web of Science ®Google Scholar
• Dube A, Nicolazzo JA, Larson I. (2011). Chitosan nanoparticles enhance the plasma exposure of (−)-epigallocatechin gallate in mice through an enhancement in intestinal stability. Eur J Pharm Sci 44:422–6
   PubMed Web of Science ®Google Scholar
• Fang JY, Hung CF, Hwang TL, Huang YL. (2005). Physicochemical characteristics and in vivo deposition of liposome-encapsulated tea catechins by topical and intratumor administrations. J Drug Target 13:19–27
   PubMed Web of Science ®Google Scholar
• Henriksen-Lacey M, Korsholm KS, Andersen P, et al. (2011). Liposomal vaccine delivery systems. Expert Opin Drug Deliv 8:505–19
   PubMed Web of Science ®Google Scholar
• Hsu YC, Liou YM. (2011). The anti-cancer effects of (−)-epigallocatechin-3-gallate on the signaling pathways associated with membrane receptors in MCF-7 cells. J Cell Physiol 226:2721–30
   PubMed Web of Science ®Google Scholar
• Hsuuw YD, Chan WH. (2007). Epigallocatechin gallate dose-dependently induces apoptosis or necrosis in human MCF-7 cells. Ann N Y Acad Sci 1095:428–40
   PubMed Web of Science ®Google Scholar
• Inoue M, Tajima K, Mizutani M, et al. (2001). Regular consumption of green tea and the risk of breast cancer recurrence: follow-up study from the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC), Japan. Cancer Lett 167:175–82
   PubMed Web of Science ®Google Scholar
• Jaruszewski KM, Ramakrishnan S, Poduslo JF, Kandimalla KK. (2011). Chitosan enhances the stability and targeting of immuno-nanovehicles to cerebro-vascular deposits of Alzheimer's disease amyloid protein. Nanomedicine 8:250--60
   Google Scholar
• Khan N, Mukhtar H. (2008). Multitargeted therapy of cancer by green tea polyphenols. Cancer Lett 269:269–80
   PubMed Web of Science ®Google Scholar
• Kim J, Zhang X, Rieger-Christ KM, et al. (2006). Suppression of Wnt signaling by the green tea compound (−)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells. Requirement of the transcriptional repressor HBP1. J Biol Chem 281:10865–75
   PubMed Web of Science ®Google Scholar
• Kushima Y, Iida K, Nagaoka Y, et al. (2009). Inhibitory effect of (−)-epigallocatechin and (−)-epigallocatechin gallate against heregulin beta1-induced migration/invasion of the MCF-7 breast carcinoma cell line. Biol Pharm Bull 32:899–904
   PubMed Web of Science ®Google Scholar
• Lambert JD, Lee MJ, Lu H, et al. (2003). Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice. J Nutr 133:4172–7
   PubMed Web of Science ®Google Scholar
• Lambert JD, Yang CS. (2003). Mechanisms of cancer prevention by tea constituents. J Nutr 133:3262S–67S
   PubMed Web of Science ®Google Scholar
• Langer R. (1998). Drug delivery and targeting. Nature 392:5–10
   PubMed Web of Science ®Google Scholar
• Lee E, Kim H, Lee IH, Jon S. (2009). In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration. J Control Release 140:79–85
   PubMed Web of Science ®Google Scholar
• Lee MJ, Maliakal P, Chen L, et al. (2002). Pharmacokinetics of tea catechins after ingestion of green tea and (−)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev 11:1025–32
   PubMed Web of Science ®Google Scholar
• Liu N, Park HJ. (2009). Chitosan-coated nanoliposome as vitamin E carrier. J Microencapsul 26:235–42
   PubMed Web of Science ®Google Scholar
• Lu H, Meng X, Li C, et al. (2003a). Glucuronides of tea catechins: enzymology of biosynthesis and biological activities. Drug Metab Dispos 31:452–61
   PubMed Web of Science ®Google Scholar
• Lu H, Meng X, Yang CS. (2003b). Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (−)-epigallocatechin gallate. Drug Metab Dispos 31:572–9
   PubMed Web of Science ®Google Scholar
• Mozafari MR. (2010). Nanoliposomes: preparation and analysis. Methods Mol Biol 605:29–50
   PubMedGoogle Scholar
• Mozafari MR, Pardakhty A, Azarmi S, et al. (2009). Role of nanocarrier systems in cancer nanotherapy. J Liposome Res 19:310–21
   PubMed Web of Science ®Google Scholar
• Nagano J, Kono S, Preston DL, Mabuchi K. (2001). A prospective study of green tea consumption and cancer incidence, Hiroshima and Nagasaki (Japan). Cancer Causes Control 12:501–8
   PubMed Web of Science ®Google Scholar
• Nakachi K, Suemasu K, Suga K, et al. (1998). Influence of drinking green tea on breast cancer malignancy among Japanese patients. Jpn J Cancer Res 89:254–61
   PubMedGoogle Scholar
• Nishiyama N. (2007). Nanomedicine: nanocarriers shape up for long life. Nat Nanotechnol 2:203–4
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. (2007). Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751–60
   PubMed Web of Science ®Google Scholar
• Sanna V, Pintus G, Roggio AM, et al. (2011). Targeted biocompatible nanoparticles for the delivery of (−)-epigallocatechin 3-gallate to prostate cancer cells. J Med Chem 54:1321–32
   PubMed Web of Science ®Google Scholar
• Sen T, Moulik S, Dutta A, et al. (2009). Multifunctional effect of epigallocatechin-3-gallate (EGCG) in downregulation of gelatinase-A (MMP-2) in human breast cancer cell line MCF-7. Life Sci 84:194–204
   PubMed Web of Science ®Google Scholar
• Shen JM, Xu L, Lu Y, et al. (2012). Chitosan-based luminescent/magnetic hybrid nanogels for insulin delivery, cell imaging, and antidiabetic research of dietary supplements. Int J Pharm 427:400–9
   PubMed Web of Science ®Google Scholar
• Siddiqui IA, Adhami VM, Bharali DJ, et al. (2009). Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res 69:1712–16
   PubMed Web of Science ®Google Scholar
• Siddiqui IA, Mukhtar H. (2010). Nanochemoprevention by bioactive food components: a perspective. Pharm Res 27:1054–60
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Tsubono Y, Nakaya N, et al. (2004). Green tea and the risk of breast cancer: pooled analysis of two prospective studies in Japan. Br J Cancer 90:1361–3
   PubMed Web of Science ®Google Scholar
• Vaidyanathan JB, Walle T. (2002). Glucuronidation and sulfation of the tea flavonoid (−)-epicatechin by the human and rat enzymes. Drug Metab Dispos 30:897–903
   PubMed Web of Science ®Google Scholar
• Wang S, Noh SK, Koo SI. (2006). Green tea catechins inhibit pancreatic phospholipase A(2) and intestinal absorption of lipids in ovariectomized rats. J Nutr Biochem 17:492–8
   PubMed Web of Science ®Google Scholar
• Warden BA, Smith LS, Beecher GR, et al. (2001). Catechins are bioavailable in men and women drinking black tea throughout the day. J Nutr 131:1731–7
   PubMed Web of Science ®Google Scholar
• Wu AH, Yu MC, Tseng CC, et al. (2003). Green tea and risk of breast cancer in Asian Americans. Int J Cancer 106:574–9
   PubMed Web of Science ®Google Scholar
• Xiong F, Mi Z, Gu N. (2011). Cationic liposomes as gene delivery system: transfection efficiency and new application. Pharmazie 66:158–64
   PubMed Web of Science ®Google Scholar
• Zhang L, Gu FX, Chan JM, et al. (2008). Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 83:761–9
   PubMed Web of Science ®Google Scholar
• Zhu M, Chen Y, Li RC. (2000). Oral absorption and bioavailability of tea catechins. Planta Med 66:444–7
   PubMed Web of Science ®Google Scholar